Officials at the generic branch of Novartis filed a rare type of lawsuit with the US District Court that may affect how the FDA regulates biogenerics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Fox, J. Sandoz sues FDA over delay in first biogeneric approval. Nat Biotechnol 23, 1327–1328 (2005). https://doi.org/10.1038/nbt1105-1327
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1105-1327
This article is cited by
-
A turbulent year at the agency
Nature Biotechnology (2006)
-
Biopharmaceutical benchmarks 2006
Nature Biotechnology (2006)
-
News In Brief
Nature Biotechnology (2006)